Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307041 | 0.82 | — | — | |
| SCHEMBL27597099 | 0.81 | — | — | |
| SCHEMBL23163789 | 0.80 | — | — | |
| SCHEMBL2721518 | 0.77 | MLYCD (0.33) | — | |
| SCHEMBL15355468 | 0.77 | — | — | |
| SCHEMBL1037403 | 0.77 | — | — | |
| SCHEMBL6415934 | 0.75 | HSP90AA1 (0.32) | — | |
| SCHEMBL980149 | 0.75 | MLYCD (0.32) | — | |
| SCHEMBL22442213 | 0.74 | KDM4E (0.33) | — | |
| SCHEMBL20958678 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018202537-A1 | PROCESS FOR THE PREPARATION OF AN AZOLIC DERIVATIVE | SEEGPHARM SA (CH) | 2018-11-08 | — | — | WO | claimed |
| CN-117062814-A | Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use | 阿维纳斯运营公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2018202537-A1 | PROCESS FOR THE PREPARATION OF AN AZOLIC DERIVATIVE | SEEGPHARM SA (CH) | 2018-11-08 | — | — | WO | disclosed |
| EP-2966071-B1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-3091007-A1 | PROCESS FOR THE PREPARATION OF PIPERIDINE COMPOUNDS | Dipharma Francis S.r.l. (IT) | 2016-11-09 | — | — | EP | disclosed |
| EP-2966071-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2612859-B1 | METHOD FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVE | KAKEN PHARMA CO LTD (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-8871942-B2 | Process for producing 1-triazole-2-butanol derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| EP-2612859-A1 | METHOD FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVE | Kaken Pharmaceutical Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-1756069-A4 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1756069-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7115601-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2005115398-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050261322-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261322-A1 | HIV integrase inhibitors | TYMP, PAICS, TYMS | DPP8 399/4885 |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | CACNA1I, MED1, ADH1A | DPP8 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.